IP Library Granted Patent US 11,737,984
Granted Patent B2
US 11,737,984 · App. 16/304,991 · Granted Aug 29, 2023

Dosage form

Inventors: Leonie Wagner-Hattler (Allschwil, CH); Maxim Puchkov (Pfeffingen, CH); Jörg Huwyler (Arlesheim, CH); Laura De Miguel (Oftringen, CH); Carolina Diaz Quijano (Oftringen, CH); Joachim Schoelkopf (Oberkulm, CH)
Assignee: Omya International AG
A61K9/2009A23L33/16A23P10/28A61K9/2072A61K9/2095A61K31/155A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,737,984
App. No.
16/304,991
Granted
Aug 29, 2023
Kind
B2
Abstract

The present invention relates to a dosage form comprising at least one functionalized calcium carbonate-comprising material (FCC) and at least one hot melt extruded polymer resin, a method for producing same, a pharmaceutical, nutraceutical, cosmetic, home and personal care product comprising the dosage form and the uses thereof.

Claims (23)

1. A carrier for a pharmaceutical, nutraceutical, cosmetic, home and personal care product dosage form consisting of a hot melt extruded composition of:

a) at least one functionalized calcium carbonate-comprising material which is a reaction product of natural ground calcium carbonate or precipitated calcium carbonate with carbon dioxide and one or more H 3 O + ion donors, wherein the carbon dioxide is formed in situ by the one or more H 3 O + ion donors treatment and/or is supplied from an external source, and

b) at least one polymer resin selected from the group comprising polyethylene, polystyrene, polyvinylchloride, polyamide 66 (nylon), polycaprolactame, polycaprolactone, acrylic polymers, acrylonitrile butadiene styrene, polybenzimidazole, polycarbonate, polyphenylene oxide/sulfide, polypopylene, teflon, polylactic acid, polylactic acid-based polymer, and aliphatic polyester,

wherein the at least one functionalized calcium carbonate-comprising material is dispersed in the composition and the weight ratio of functionalized calcium carbonate-comprising material to polymer resin ranges from 95:5 to 5:95;

wherein the carrier is a powder, tablets, mini-tablets, granules, pellets, capsules or tablet-in-cup

and

c) an optional active ingredient, wherein the active agent is

i) loaded onto or mixed with the composition,

ii) dispersed in the composition,

iii) is in form of a core, which is at least partially covered by the composition, or

iv) in form of a layer which at least partially covers a core, made from the composition, or

e) in form of a layered structure of at least two layers, wherein at least one layer is made from the composition.

2. The carrier of claim 1 , wherein the natural ground calcium carbonate is selected from calcium carbonate containing minerals selected from the group comprising marble, chalk, dolomite, limestone and mixtures thereof, or the precipitated calcium carbonate is selected from the group comprising precipitated calcium carbonates having aragonitic, vateritic or calcitic mineralogical crystal forms and mixtures thereof.

3. The carrier according to claim 1 , wherein the at least one functionalized calcium carbonate-comprising material:

a) has a BET specific surface area of from 20 m 2 /g to 450 m 2 /g measured using nitrogen and BET method according to ISO 9277; and/or

b) comprises particles having a volume median grain diameter d 50 (vol) of from 1 μm to 50 μm; and/or

has an intra-particle intruded specific pore volume within a range of 0.15 to 1.35 cm 3 /g, calculated from a mercury intrusion porosimetry measurement.

4. A carrier for a pharmaceutical, nutraceutical, cosmetic, home and personal care product dosage form consisting of a hot melt extruded composition of:

a) at least one functionalized calcium carbonate-comprising material which is a reaction product of natural ground calcium carbonate or precipitated calcium carbonate with carbon dioxide and one or more H 3 O + ion donors, wherein the carbon dioxide is formed in situ by the one or more H 3 O + ion donors treatment and/or is supplied from an external source,

b) at least one polymer resin selected from the group comprising polyethylene, polystyrene, polyvinylchloride, polyamide 66 (nylon), polycaprolactame, polycaprolactone, acrylic polymers, acrylonitrile butadiene styrene, polybenzimidazole, polycarbonate, polyphenylene oxide/sulfide, polypopylene, teflon, polylactic acid, polylactic acid-based polymer, and aliphatic polyester, and

c) an active agent and/or a prodrug thereof;

wherein the at least one functionalized calcium carbonate-comprising material is dispersed in the composition and a weight ratio of functionalized calcium carbonate-comprising material to hot melt extruded polymer resin ranges from 95:5 to 5:95;

wherein the carrier is in form of powder, tablets, mini-tablets, granules, pellets, capsules or tablet-in-cup.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2019
From: WAGNER-HATTLER, LEONIE; PUCHKOV, MAXIM; HUWYLER, JÖRG; DE MIGUEL, LAURA; DIAZ QUIJANO, CAROLINA; SCHOELKOPF, JOACHIM
To: OMYA INTERNATIONAL AG
Reel/Frame 047917/0878 →
Priority Claims (1)
EP 16179526 · Jul 14, 2016 · regional
Continuity (2)
Provisional Application 62364913 · Jul 21, 2016
Related Publication 20200155458A1 · May 21, 2020